In patients with CD who have active perianal fistulas and uveitis, which biologic, anti‑TNF, ustekinumab, or vedolizumab, is preferred to address both intestinal and ocular inflammation

anti-TNF has the strongest evidence for both problems: guidelines recommend infliximab for induction and maintenance in complex perianal fistulizing crohn's disease ^1,2, and anti-TNFs (best evidence for infliximab) are the biologic of choice for IBD-associated uveitis, which itself runs an independent course and should be co-managed as an ophthalmologic emergency ^3,4. ustekinumab is a reasonable alternative. It may be effective for perianal fistulas and has controlled recurrent non-infectious uveitis where anti-TNF was ineffective or contraindicated ^1,5–8. Whereas vedolizumab is the weakest option, with only about one-third fistula healing in a meta-analysis and limited extraintestinal efficacy owing to its gut-selective mechanism ^1,9. ^1–7,9

What is known: - Guidelines recommend infliximab (adalimumab also usable) for complex perianal fistulae in crohn's, with better healing at higher trough levels. ^1,2 - For uveitis, anti-TNFs are the listed biologic (best evidence infliximab), and uveitis typically runs a course independent of bowel activity. ^3,4 - Ustekinumab controlled severe recurrent non-infectious uveitis in crohn's patients where adalimumab had failed, and may be effective for fistulas. ^1,5–7 - Vedolizumab healed perianal fistulas in about one-third of patients and has limited extraintestinal efficacy due to its gut-specific mechanism. ^1,9

What is unknown / caveats: - One panel judged vedolizumab/ustekinumab 'appropriate' for perianal disease in general but anti-TNF 'inappropriate/uncertain' only in specific comorbid scenarios (malignancy/infection) ¹⁰ - No head-to-head trial compares these three biologics for combined fistula-plus-uveitis outcomes - Uveitis evidence for ustekinumab is limited to small case reports/registry data - Vedolizumab and ustekinumab efficacy is described mainly for luminal/fistula disease, not ocular EIM - The relative benefit of ustekinumab versus anti-TNF for co-existing uveitis rests on small uncontrolled reports rather than comparative trials.

## References

1. Marsal J, Barreiro-de Acosta M, Blumenstein I, Cappello M, Bazin T, Sebastian S. Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Front Med (Lausanne). 2022. PMID: 35783628.

2. Cheung O, Regueiro Miguel D. Inflammatory bowel disease emergencies. Gastroenterol Clin North Am. 2003;32:1269-88. PMID: 14696307.

3. Tie Y, Huang Y, Chen R, Li L, Chen M, Zhang S. Current insights on the roles of gut microbiota in inflammatory bowel disease-associated extra-intestinal manifestations: pathophysiology and therapeutic targets. Gut Microbes. 2023. PMID: 37822139.

4. Greuter T, Rieder F, Kucharzik T, Peyrin-Biroulet L, Schoepfer AM, Rubin DT, Vavricka SR. Emerging treatment options for extraintestinal manifestations in IBD. Gut. 2021. PMID: 32847845.

5. Ahuja V, Hilmi I, Ye BD, Ling KL, Ng SC, Leong RW, Kumar P, Khoo XH, Makharia GK, Sollano J, Pisespongsa P, Mustaffa N, Banerjee R, Leow AH, Raja Ali RA, Chuah SW, Palaniappan S, Ooi CJ, Leung WK. Ten missteps in the management of inflammatory bowel disease in Asia: An expert report by the Asian Pacific Association of Gastroenterology Working Group on Inflammatory Bowel Disease. J Gastroenterol Hepatol. 2024;39(8):1500-1508. PMID: 38725188.

6. Mocci G, Tursi A, Onidi FM, Usai-Satta P, Pes GM, Dore MP. Ustekinumab in the Treatment of Inflammatory Bowel Diseases: Evolving Paradigms. J Clin Med. 2024;13(5):ePub only. PMID: 38592377.

7. Rodriguez Duran M, O'Keefe GAD. Ocular extraintestinal manifestations and treatments in patients with inflammatory bowel disease. Front Ophthalmol (Lausanne). 2023. PMID: 38983096.

8. Straatmijer T, Biemans VBC, Hoentjen F, de Boer NKH, Bodelier AGL, Dijkstra G, van Dop WA, Haans JJL, Jansen JM, Maljaars PWJ, van der Marel S, Oldenburg B, Ponsioen CY, Visschedijk MC, de Vries AC, West RL, van der Woude CJ, Pierik M, Duijvestein M, van der Meulen-de Jong AE. Ustekinuma b for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study. J Crohns Colitis. 2021;15(11):1920-1930. PMID: 33909062.

9. Peter CD, Huang YH, Tian WN. Dual biologic therapy for severe ulcerative colitis, concomitant extraintestinal manifestations and an orbital osteoma: a successful treatment. Rev Esp Enferm Dig. 2022. PMID: 35770593.

10. Weizman AV, Nguyen GC, Seow CH, Targownik L, Murthy SK, Boland K, Afzal NM, Khanna R, Jones J, Afif W, Halder S, Reinglas J, Fowler S, Huang V, Kaplan GG, Melmed GY. Appropriateness of Biologics in the Management of Crohn's Disease Using RAND/UCLA Appropriateness Methodology. Inflamm Bowel Dis. 2019;25(2):328-335. PMID: 30346529.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

---

_Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct._